Caracterización, procesos y estructuras para la mejora de células solares de silicio

Partiendo de los desarrollos tecnológicos previos introducidos por el instituto de Energía Solar de la UPM, la tesis presenta un camino de mejora de las células de P/Al de emisor profundo del Instituto, introduciendo una nueva tecnología basada en la realización de un contacto posterior local en las células, y la sustitución del proceso de "Gettering" de Aluminio por un proceso de "Gettering" de fósforo. En la tesis se tratan por tanto temas relacionados con la optimización y caracterización de los procesos de fabricación de estas células, así como temas relacionados con el material de partida del entorno industrial (el silicio Cz), y su utilización en estos procesos. De esta forma, diferentes análisis y experimentos se han realizado cubriendo un amplio abanico tecnológico; así algunos de los resultados y temas más destacables contenidos en la tesis son: La optimización del proceso de gettering alcanzando un máximo para la recuperación del tiempo de vida en volumen a una temperatura determinada durante un tiempo fijo. La caracterización del proceso de segregación que tiene lugar durante el "Gettering " de fósforo, encontrándose que este proceso sufre un cambio a alta temperatura que podría justificarse por el paso de una segregación sólido-sólido a una sólido-líquido. El desarrollo de diversos procesos de fabricación con contacto local posterior que han alcanzado eficiencias de conversión en células del 18%. El estudio del defecto metaestable asociado al O-B del silicio Cz y su interacción con algunos procesos de fabricación, especialmente con el gettering de fósforo. Además se muestran resultados de experimentos orientados a evaluar la influencia de otros defectos como son los autointersticiales en la reducción del defecto metaestable asociado al contenido de O-B. El análisis de nuevos materiales, que no presentan degradación con la luz, como son el silicio Cz dopado con galio y el silicio FZ fotovoltaico en su aplicación a los procesos de fabricación desarrollados. Y el análisis de la reducción del espesor de las células, la influencia del tiempo de vida en el volumen y la pasivación de la superficie posterior en su respuesta. Presentándose resultados experimentales de eficiencias en células delgadas del 17.4 % (en células de 100 micras de espesor sobre silicio Cz)

SIMIF-3: Sistema de Información Meteorológica para Incendios Forestales

Ponencia presentada en: XXXIII Jornadas Científicas de la AME y el XIV Encuentro Hispano Luso de Meteorología celebrado en Oviedo, del 7 al 9 de abril de 2014

Controlling the artificial radiance of the night sky: The Añora urban laboratory

We provide radiometric evidence of the relevance of nearby light sources on the artificial brightness of the night sky. To obtain the required data we developed a method based on the use of power-regulated urban lighting systems, which also provides relevant information on the propagation of light pollution at short distances from the sources. A controlled experiment was carried out in the Andalusian municipality of Añora (1526 inhab.) in which the radiant power of its regulated public outdoor lighting system was modified in a predefined way during the central part of the night while continuously recording the zenithsky brightness in the TESS-W photometric band from two separate locations inside the town. We determined that the power regulated streetlight sources contribute a 60–62% to the total zenith sky brightness at these observing locations in clear and moonless nights when operated at their maximum power rating, being the remaining sky radiance due to constant local sources and sources from neighboring towns. These results, in combination with georeferenced information on the sources’ location and properties, impose some constraints on the functional form of the effective point-spread functions (PSF) of the zenith sky brightness at short distances from the sources. For the conditions of our experiment we have found that the expected exponents of power-law PSFs are close to -1

Comprensión medular como debut de sarcoma mieloide con amplia afectación ósea

Myeloid sarcoma is an extramedullary tumor usually found in patients with previous hematological neoplasms, with symptoms depending on the location of the lesions due to their mass effect. The main locations are lymph nodes and the skin. It requires a high clinical suspicion for its diagnosis and has a poor prognosis in the short-medium term. We present a clinical case of a 64-year-old man with no hematological history who consulted for bone pain and spinal cord compression, observing extensive bone involvement on MRI and PET-TC. He suffered a nosocomial infectious complication and died in the ICU awaiting histological diagnostic confirmation.El sarcoma mieloide es un tumor extramedular que suele encontrarse en pacientes con neoplasias hematológicas previas, con síntomas en función de la localización de las lesiones, debido al efecto masa que producen. Las principales localizaciones son ganglionares y cutáneas. Precisa una alta sospecha clínica para su diagnóstico, y presenta un mal pronóstico a corto y a medio plazo. Se presenta un caso clínico de un varón de 64 años sin antecedentes hematológicos que debuta con dolores óseos y compresión medular, observando amplia afectación ósea en una resonancia magnética nuclear (RMN) y una tomografía por emisión de positrones (PET-TAC). Sufre complicación infecciosa nosocomial y fallece en la UCI en esperas de confirmación diagnóstica histológica.

Modelo prolab: S.O.S. Kids, educación para todos

La Educación Especial como concepto de Estado, debe ser un servicio complementario personalizado para estudiantes del sistema educativo regular. Del total de estudiantes, 383,000.00 niños poseen dificultades de desarrollo (estimaciones indican que aumentará a 440,300 niños para el año 2030) y el 50% de los individuos con discapacidad que reciben servicios de educación pública se encuentran en Lima (El sistema educativo nacional atiende al 3%). Existe falta de asesoría y soporte especializado que aclare mitos y creencias equívocas que socavan la capacidad de los padres para buscar asesoría adecuada y poder reinsertar al niño a la sociedad de manera oportuna. Añadido a esto, las restricciones geográficas impiden a los niños el acceso a una educación especializada. El centro asistencial SOS Kids es un centro que inició operaciones a partir de septiembre del 2021. En el centro se brinda tratamiento a problemas en el desarrollo, comportamiento o diagnósticos. Desde un punto de vista de negocio, la firma no se ha constituido como empresa y, debido al panorama económico, existen muchos retos para mantenerse en el mercado. Es aquí, donde entra a tallar la propuesta de innovación incremental de servicio específico actuaremos como capital ángel, para transformar el negocio. Esto consiste en adecuar la infraestructura, implementar un ciclo de tratamiento completo (Diagnóstico, evaluación, logro de objetivos, reevaluación y control médico), soporte a través de una APP que permitirá una orientación 24/7@365 para padres y un programa de escuela para padres durante todo el ciclo terapéutico, para ello se realizará una inyección de capital de 100,000 PEN.Special Education as a State concept must be a personalized complementary service for students of the regular education system. Of the total number of students, 383,000.00 children have development difficulties (estimates indicate that it will increase to 440,300 children by the year 2030) and 50% of the population with disabilities that access the national educational service is in Lima (The national educational system attends the 3%). There is a lack of specialized advice and support to clarify myths and misconceptions that undermine the ability of parents to seek adequate advice and be able to reintegrate the child into society in a timely manner. Added to this, geographical restrictions prevent children from accessing specialized education. The SOS Kids assistance center is a center that began operations as of September 2021. The center provides treatment for developmental, behavioral, or diagnostic problems. From a business point of view, the firm has not been incorporated as a company and, due to the economic outlook, there are many challenges to stay in the market. This is where the incremental innovation proposal for a specific service comes into play. We will act as angel capital to transform the business. This consists of adapting the infrastructure, implementing a complete treatment cycle (Diagnosis, evaluation, achievement of objectives, re-evaluation and medical control), and support through an APP that will allow 24/7@365 orientation for parents and a school program for parents throughout the therapeutic cycle, for which a capital injection of 100,000 PEN will be made

Definición de retiros en cuencas urbanas.

Se propone en este trabajo una metodología para la definición de los retiros en cuencas urbanas altamente intervenidas, en función de elementos tales como: capacidad hidráulica del río, estabilidad de márgenes y taludes del cauce, franjas para zonas ornamentales y recreación pasiva, franjas de terreno para la extensión de redes de servicios públicos, zonas para la circulación, vías vehiculares o peatonales, zonas de amortiguación para la protección de los ecosistemas en los cauces y las riberas y acceso al cauce y a las zonas de amortiguación para su mantenimiento

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel or tisa-cel were retrospectively collected from 12 Spanish centers. A total of 307 patients underwent apheresis for axi-cel (n=152) and tisa-cel (n=155) from November 2018 to August 2021, of which 261 (85%) received a CAR T infusion (88% and 82%, respectively). Median time from apheresis to infusion was 41 days for axi-cel and 52 days for tisa-cel (P=0.006). None of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs. 73%, P=0.003, and 42% vs. 16%, P= 2 and progressive disease before lympho-depletion. Safety and efficacy results in our real-world experience were comparable with those reported in the pivotal trials. Patients treated with axi-cel experienced more toxicity but similar non-relapse mortality compared with those re-ceiving tisa-cel. Efficacy was not significantly different between both products

Buenas Prácticas en los Programas Universitarios para Mayores en España

Ana Isabel Muñoz Alcón y Francisco Trullén Galve (Universidad Catolica de Ávila); María P. García de la Torre y Francisco Ascón Belver (Universidad de A Coruña); M. Isabel Luis Rico, Ángel Gañán Adánez, Tamara de la Torre Cruz, Vanesa Baños Martínez (Universidad de Burgos); Yolanda Lázaro Fernández y Jaime Cuenca Amigo (Universidad de Deusto); Camino Caballero Posado (Universidad de Extremadura); Mª Adoración Holgado Sánchez y Mª Teresa Ramos Bernal (Universidad Pontificia de Salamanca); Sara Serrate González, Javier Alba Barrios y José Manuel Muñoz Rodríguez; Miguel Ángel Nombela Castaño (Universidad de Vigo

Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study

In the pre-chimeric antigen receptor T cell (CAR-T) therapy era, the SCHOLAR-1 study identified a group of patients with refractory aggressive B cell lymphoma (ABCL) with particularly poor prognoses. We recently published our real -world data from Spain, focused on this SCHOLAR-1 refractory group, and compared patients who underwent CAR-T therapy with the previous standard of care. In this study, we found that the efficacy of CAR-T therapy in refractory patients, in terms of progression-free survival (PFS) and overall survival (OS), was superior to that of the treatments available in the pre-CAR-T era. The main objective of these new analyses was to analyze treatment efficacy in terms of response rates and survival for patients with ABCL with or without the SCHOLAR-1 criteria. In addition, we ana-lyzed the prognostic impact of each SCHOLAR-1 criterion independently. Our study aimed to assess the prognostic impact of SCHOLAR-1 criteria on ABCL patients treated with CAR-T therapy in Spain. This multicenter, retrospective, observational study. We included all adult patients treated with commercially available CAR-T cell products and diag-nosed with ABCL different from primary mediastinal large B cell lymphoma between February 2019 and July 2022. Patients meeting any SCHOLAR-1 criteria (progressive disease as the best response to any line of therapy, stable dis-ease as the best response to >4 cycles of first-line therapy or >2 cycles of later-line therapy, or relapse at <12 months after autologous stem cell transplantation [auto-SCT]) in the line of treatment before CAR-T therapy (SCHOLAR-1 group) were compared with those not meeting any of these criteria (non-SCHOLAR-1 group). To analyze the prognos-tic impact of individual SCHOLAR-1 criteria, all the patients who met any of the SCHOLAR-1 criteria at any time were included to assess whether these criteria have the same prognostic impact in the CAR-T era. In addition, patients were grouped according to whether they were refractory to the first line of treatment, refractory to the last line of treatment, or relapsed early after auto-SCT. The PFS and OS were calculated from the time of appearance of the SCHOLAR-1 refractoriness criteria. Of 329 patients treated with CAR-T (169 with axi-cel and 160 with tisa-cel), 52 were in the non-SCHOLAR-1 group and 277 were in the SCHOLAR-1 group. We found significantly better outcomes in the non-SCHOLAR-1 patients compared with the SCHOLAR-1 patients (median PFS of 12.2 and 3.3 months, respectively; P = .009). In addition, axi-cel showed better results in terms of efficacy than tisa-cel for both the non SCHOLAR-1 group (hazard ratio [HR] for PFS, 2.7 [95% confidence interval (CI), 1.1 to 6.7; P = .028]; HR for OS, 7.1 [95% CI, 1.5 to 34.6; P = .015]) and SCHOLAR-1 group (HR for PFS, 1.8 [95% CI, 1.3 to 2.5; P < .001]; HR for OS, 1.8 [95% CI, 1.2 to 2.6; P = .002]), but also significantly more toxicity. Finally, separately analyzing the prognostic impact of each SCHOLAR-1 criterion revealed that refractoriness to the last line of treatment was the variable with the most significant impact on survival. In conclusion, SCHOLAR-1 refractoriness criteria notably influence the efficacy of CAR-T therapy. In our experience, axi-cel showed better efficacy than tisa-cel for both SCHOLAR-1 and non-SCHOLAR-1 patients. Refractoriness to the last line of treatment was the variable with the most significant impact on survival in the CAR-T therapy era.(c) 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc